Evidence map›Paper›PMID 40021095›Full record

ArticleNeurobiology of disease2025

Potentiation of the M

Mackenzie Smith, Grace E Dodis, Amanda M Vanderplow, Sonia Gonzalez, Yewon Rhee, Karie Scrogin, Rocco G Gogliotti

Abstract read
In one paragraph

Article in Neurobiology of disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Mackenzie SmithDepartment of Molecular Pharmacology and Neuroscience, Loyola University Chicago, 2160 S 1st Avenue, Maywood, IL 60153, USA; Edward Hines Jr. VA Hospital, 5000 5th Ave, Hines, IL 60141, USA.
Grace E DodisDepartment of Molecular Pharmacology and Neuroscience, Loyola University Chicago, 2160 S 1st Avenue, Maywood, IL 60153, USA; Edward Hines Jr. VA Hospital, 5000 5th Ave, Hines, IL 60141, USA.
Amanda M VanderplowDepartment of Molecular Pharmacology and Neuroscience, Loyola University Chicago, 2160 S 1st Avenue, Maywood, IL 60153, USA; Edward Hines Jr. VA Hospital, 5000 5th Ave, Hines, IL 60141, USA.
Sonia GonzalezDepartment of Molecular Pharmacology and Neuroscience, Loyola University Chicago, 2160 S 1st Avenue, Maywood, IL 60153, USA; Edward Hines Jr. VA Hospital, 5000 5th Ave, Hines, IL 60141, USA.
Yewon RheeDepartment of Molecular Pharmacology and Neuroscience, Loyola University Chicago, 2160 S 1st Avenue, Maywood, IL 60153, USA; Edward Hines Jr. VA Hospital, 5000 5th Ave, Hines, IL 60141, USA.
Karie ScroginDepartment of Molecular Pharmacology and Neuroscience, Loyola University Chicago, 2160 S 1st Avenue, Maywood, IL 60153, USA; Edward Hines Jr. VA Hospital, 5000 5th Ave, Hines, IL 60141, USA.
Rocco G GogliottiDepartment of Molecular Pharmacology and Neuroscience, Loyola University Chicago, 2160 S 1st Avenue, Maywood, IL 60153, USA; Edward Hines Jr. VA Hospital, 5000 5th Ave, Hines, IL 60141, USA. Electronic address: rgogliotti@luc.edu.

Funding

Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disordersR01MH124671 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG, NISWENDER, COLLEEN M · 2020 to 2024
$3.5M
A precision medicine approach to Rett SyndromeR01NS112171 · NINDS · LOYOLA UNIVERSITY CHICAGO · PI GOGLIOTTI, ROCCO GEORGE · 2020 to 2024
$1.7M
miRNA site-blocking ASOs as MeCP2 targeted therapeuticsR21HD111864 · NICHD · LOYOLA UNIVERSITY CHICAGO · PI GOGLIOTTI, ROCCO GEORGE · 2023 to 2024
$424k
Targeting MeCP2-Associated Disorders with miRNA Site-Blocking OligonucleotidesF32HD113386 · NICHD · LOYOLA UNIVERSITY CHICAGO · PI VANDERPLOW, AMANDA · 2024 to 2025
$136k
The interplay of the heat shock cascade and Rett syndromeF31NS134246 · NINDS · LOYOLA UNIVERSITY CHICAGO · PI Sonia Gonzalez · 2024 to 2026
$105k
NICHD NIH HHS F32 HD113386NICHD NIH HHS R21 HD111864NIMH NIH HHS R01 MH124671NINDS NIH HHS F31 NS134246NINDS NIH HHS R01 NS112171
6 · The paper itself

Abstract

Rett syndrome (RTT) is a neurodevelopmental disorder that is caused by loss-of-function mutations in the methyl-CpG binding protein 2 (MeCP2) gene. RTT patients experience a myriad of debilitating symptoms, which include respiratory phenotypes that are often associated with lethality. Our previous work established that expression of the M

Indexed as

ApneaMethyl-CpG-Binding Protein 2NeuronsReceptor, Muscarinic M1Rett SyndromeAnimalsBrainDisease Models, AnimalFemaleMaleMiceMice, Inbred C57BLMice, TransgenicMecp2 protein, mouseMethyl-CpG-Binding Protein 2Receptor, Muscarinic M1ApneasC-FosLight sheet imagingM1 mAchRRett syndrome

Identifiers

PMID40021095
PMCPMC12076212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.